On October 5, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for oncology targets, reported a collaborative agreement for the development, manufacture, and supply of CT83 (KK-LC-1) mAb(Press release, T-Cure Bioscience, OCT 5, 2021, View Source [SID1234590827]). These will be used to develop a diagnostic test to identify tumors that express KK-LC-1. Patients with KK-LC-1 positive tumors may be eligible inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Atlas Antibodies AB will provide all manufacturing and product supply for KK-LC-1 mAb for the companion diagnostic for clinical development. T-Cure is developing TCR-T therapeutics targeting Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) for gastric, triple negative breast cancer, cervical, lung and other KK-LC-1 positive cancers.
T-Cure plans to develop the companion diagnostic assay to identify KK-LC-1 positive cancer patients for inclusion in the company sponsor clinical trial planned for 2022.
"We are excited that Atlas Antibodies will supply high quality mAb shown to have superior specificity in recognizing KK-LC-1 in the patients’ samples." stated Gang Zeng, Ph.D., Chief Executive Officer at T-Cure Bioscience. "Developing an immnunohistochemistry (IHC) diagnostic tool is key to identify the right patient population to be treated by our KK-LC-1 specific TCR-T."
We are delighted to start this collaboration with T-Cure Bioscience. It reflects one of our new business models of deploying our highly validated monoclonals through contract manufacturing in which both parties are enabled to focus on their core competencies," stated Nille Klæbel, Chief Executive Officer at Atlas Antibodies. "We are convinced that this creates a win-win situation for both parties.